| Crystal structure of SARS-CoV-2
main protease provides a basis for design of improved α-ketoamide
inhibitors |
Science (April 24, 2020) |
small molecules (peptidomimetic
α-ketoamides) |
(59) |
| A human monoclonal antibody
blocking SARS-CoV-2 infection |
Nature Communications (May 4,
2020) |
antibodies |
(100) |
| A SARS-CoV-2 protein interaction
map reveals targets for drug repurposing |
Nature (April
30, 2020) |
small molecules
with different
actions |
(5) |
| An orally bioavailable broad-spectrum
antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures
and multiple coronaviruses in mice |
Science Translational
Medicine (April 29, 2020) |
ribonucleoside analog that
is also effective against CoV mutations resistant to remdesivir |
(91) |
| Computational design of
ACE2-based peptide inhibitors of SARS-CoV-2 |
ACS Nano (April 14, 2020) |
helical peptides that can
be attached to nanoparticles and dendrimers |
(501) |
| COVID-19:
combining antiviral
and anti-inflammatory treatments |
Lancet Infectious
Diseases (February 27, 2020) |
baricitinib as an inhibitor
of NAK family, especially for AAK1 |
(502) |
| COVID-19:
immunopathology
and its implications for therapy |
Nature Reviews Immunology (April
9, 2020) |
biologics |
(503) |
| Development of CRIPSR as
an Antiviral Strategy to Combat SARS-CoV-2 and Influenza |
Cell (April
29, 2020) |
Cas13d-crRNAs |
(504) |
| Cross-neutralization of
SARS-CoV-2 by a human monoclonal SARS-CoV antibody |
Nature (May
18, 2020) |
human anti-SARS-CoV-2
S
protein specific monoclonal antibody |
(102) |
| Inhibition
of SARS-CoV-2
infections in engineered human tissues using clinical-grade soluble
human ACE2 |
Cell (May
14, 2020) |
human recombinant
soluble
ACE2 |
(96) |
| Network-based drug repurposing
for novel coronavirus 2019-nCoV/SARS-CoV-2 |
Cell Discovery (March 16, 2020) |
various small molecules |
(153) |
| Rapid identification of
potential inhibitors of SARS-CoV-2 main protease by deep docking of
1.3 billion compounds |
Molecular Informatics (March 11, 2020) |
1000 potential ligands for
SARS-CoV-2 3CLpro |
(505) |
| Repurposing therapeutics
for COVID-19: Supercomputer-based docking to the SARS-CoV-2 viral
spike protein and viral spike protein-human ACE2 interface |
ChemRxiv (February 27, 2020) |
48 potential small-molecule
hits for S-protein–ACE2 interface and 30 hits for S protein
alone |
(506) |
| Therapeutic options for
the 2019 novel coronavirus (2019-nCoV) |
Nature Reviews Drug
Discovery (February 10, 2020) |
various small molecules
and biologics |
(8) |
| Potent neutralizing antibodies
against SARS-CoV-2 identified by high-throughput single-cell sequencing
of convalescent patients’ B cells |
Cell (May
13, 2020) |
neutralizing
antibodies |
(98) |
